SAMADDER, Pounami, Rakesh AITHAL, Ondrej BELÁŇ and Lumír KREJČÍ. Cancer TARGETases: DSB Repair as a Pharmacological Target. Pharmacology & Therapeutics. Kidlington: Pergamon-Elsevier Science LTD, 2016, vol. 161, "May", p. 111-131. ISSN 0163-7258. Available from: https://dx.doi.org/10.1016/j.pharmthera.2016.02.007.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cancer TARGETases: DSB Repair as a Pharmacological Target
Authors SAMADDER, Pounami (356 India, belonging to the institution), Rakesh AITHAL (356 India, belonging to the institution), Ondrej BELÁŇ (703 Slovakia, belonging to the institution) and Lumír KREJČÍ (203 Czech Republic, belonging to the institution).
Edition Pharmacology & Therapeutics, Kidlington, Pergamon-Elsevier Science LTD, 2016, 0163-7258.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 11.127
RIV identification code RIV/00216224:14110/16:00087848
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.pharmthera.2016.02.007
UT WoS 000375886600009
Keywords in English DSB repair; genome instability; cancer; kinases; helicases; nucleases
Tags EL OK, podil
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 5/10/2016 16:24.
Abstract
Cancer is a disease attributed to the accumulation of DNA damages due to incapacitation of DNA repair pathways resulting in genomic instability and a mutator phenotype. Among the DNA lesions, double stranded breaks (DSBs) are the most toxic forms of DNA damage which may arise as a result of extrinsic DNA damaging agents or intrinsic replication stress in fast proliferating cancer cells. Accurate repair of DSBs are therefore paramount to the cell survival, and several classes of proteins such as kinases, nucleases, helicases or core recombinational proteins have pre-defined jobs in precise execution of DSB repair pathways. On one hand, the proper functioning of these proteins ensures maintenance of genomic stability in normal cells, and on the other hand results in resistance to various drugs employed in cancer therapy and therefore present a suitable opportunity for therapeutic targeting. Higher relapse and resistance in cancer patients due to non-specific, cytotoxic therapies is an alarming situation and it is becoming more evident to employ personalized treatment based on the genetic landscape of the cancer cells. For the success of personalized treatment, it is of immense importance to identify more suitable targetable proteins in DSB repair pathways and also to explore new synthetic lethal interactions with these pathways. Here we review the various alternative approaches to target the various protein classes termed as cancer TARGETases in DSB repair pathway to obtain more beneficial and selective therapy.
Links
GAP207/12/2323, research and development projectName: Endonuleazová a translokázová aktivita v restričních-modifikáčních komplexéch typu I
Investor: Czech Science Foundation
GA13-26629S, research and development projectName: SUMO a stability genomu
Investor: Czech Science Foundation
MUNI/M/1894/2014, interní kód MUName: Development of new MUS81 nuclease inhibitors as chemical biology probe with clinical progression
Investor: Masaryk University, INTERDISCIPLINARY - Interdisciplinary research projects
NV15-33999A, research and development projectName: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality
PrintDisplayed: 20/7/2024 20:34